Biofrontera AG (LTS:0DOL) Insider Ownership: 0.00 % (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0DOL Biofrontera AG LTS:0DOL
61 GF Score
Price €2.44
GF Value €2.34
! 4 Warning Signs
View Full Analysis

What is Biofrontera AG Insider Ownership?

Biofrontera AG LTS:0DOL -3.56% 61 Insider Ownership is 0.00 % as of Sep. 05, 2026. GuruFocus rates LTS:0DOL with a GF Score™ of 61/100 and a GF Value™ of €2.34. The stock has 4 warning signs investors should review.

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biofrontera AG's insider ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biofrontera AG's Institutional Ownership is 0.05%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biofrontera AG's Float Percentage Of Total Shares Outstanding is 0.00%.

Biofrontera AG Insider Ownership Historical Data

* Premium members only.

The historical data trend for Biofrontera AG's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera AG Insider Ownership Chart

Biofrontera AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Insider Ownership
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Biofrontera AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Insider Ownership Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0DOL
61GF Score
Biofrontera AG LTS:0DOL
Insider Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofrontera AG Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

Frequently Asked Questions Learn more about Insider Ownership →
What does a Insider Ownership of 0.00 % mean?
Biofrontera AG (LTS:0DOL) has a Insider Ownership of 0.00 % as of Sep. 05, 2026. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Biofrontera AG and its competitors.
Is Biofrontera AG's Insider Ownership too high?
Biofrontera AG's current Insider Ownership is 0.00 %. Overall, Biofrontera AG has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Biofrontera AG's Insider Ownership compare to ZTS and UTHR?
Biofrontera AG's Insider Ownership of 0.00 % can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Insider Ownership for a Drug Manufacturers company?
A good Insider Ownership depends on the Drug Manufacturers industry context. However, Insider Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Insider Ownership mean?
A high Insider Ownership can signal that a stock is expensive relative to its fundamentals. Insider ownership equals the percent of shares owned by company insiders relative to total shares. View historical data on Biofrontera AG and its competitors. Biofrontera AG's current Insider Ownership is 0.00 %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera AG stock overvalued right now?
Biofrontera AG (LTS:0DOL) has a current Insider Ownership of 0.00 %. The stock's GF Value™ is €2.34, compared to a current price of €2.44 — trading 4.3% above its estimated fair value. The current Insider Ownership is 0.00 %. Biofrontera AG's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Insider Ownership calculated?
Insider Ownership is calculated from a company's financial statements. For Biofrontera AG (LTS:0DOL), the current Insider Ownership is 0.00 % as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofrontera AG (LTS:0DOL) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera AG stock appears to be overvalued. The current stock price of €2.44 is trading 4.3% above its estimated GF Value™ of €2.34.

Key valuation signals for LTS:0DOL:

  • Insider Ownership: 0.00 %
  • GF Value™: €2.34 vs. price of €2.44 (4.3% above fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the LTS:0DOL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera AG Business Description

Other Exchanges B8FK:Germany
Address Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
61GF Score

Get the complete analysis for LTS:0DOL

Insider Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.44
Price
€2.34
GF Value